NO964758L - Anvendelse av von Willebrand-faktor og farmasöytiske preparater - Google Patents

Anvendelse av von Willebrand-faktor og farmasöytiske preparater

Info

Publication number
NO964758L
NO964758L NO964758A NO964758A NO964758L NO 964758 L NO964758 L NO 964758L NO 964758 A NO964758 A NO 964758A NO 964758 A NO964758 A NO 964758A NO 964758 L NO964758 L NO 964758L
Authority
NO
Norway
Prior art keywords
vwf
preparation
fraction
pharmaceutical preparation
von willebrand
Prior art date
Application number
NO964758A
Other languages
English (en)
Norwegian (no)
Other versions
NO964758D0 (no
Inventor
Hans-Peter Schwarz
Peter Turecek
Johann Eibl
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19616540A external-priority patent/DE19616540A1/de
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of NO964758D0 publication Critical patent/NO964758D0/no
Publication of NO964758L publication Critical patent/NO964758L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO964758A 1995-11-10 1996-11-08 Anvendelse av von Willebrand-faktor og farmasöytiske preparater NO964758L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19542004 1995-11-10
DE19616540A DE19616540A1 (de) 1995-11-10 1996-04-25 Verwendung von von Willebrand-Faktor und pharmazeutische Zubereitung

Publications (2)

Publication Number Publication Date
NO964758D0 NO964758D0 (no) 1996-11-08
NO964758L true NO964758L (no) 1997-05-12

Family

ID=26020274

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964758A NO964758L (no) 1995-11-10 1996-11-08 Anvendelse av von Willebrand-faktor og farmasöytiske preparater

Country Status (5)

Country Link
US (1) US6005077A (fr)
EP (1) EP0774261A3 (fr)
JP (1) JPH09221432A (fr)
CA (1) CA2189947C (fr)
NO (1) NO964758L (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
US5958716A (en) * 1996-06-06 1999-09-28 Dade Behring Inc. Blood factor assay
US6531577B1 (en) * 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6605222B1 (en) * 1998-05-20 2003-08-12 Baxter Aktiengesellschaft Method for producing a factor VIII/von Willebrand factor complex
JP4663837B2 (ja) * 1999-12-24 2011-04-06 一般財団法人化学及血清療法研究所 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
EP1240900B1 (fr) * 1999-12-24 2009-05-06 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Facteur viii ou facteur von willebrand pour le traitement de maladies hemorragiques associant la thrombopathie
DE19964109A1 (de) * 1999-12-29 2001-07-05 Dade Behring Marburg Gmbh Gebrauchsfertiges langzeitstabiles Ristocetin Cofaktor Testreagenz
EP1148063A1 (fr) * 2000-04-18 2001-10-24 Octapharma AG Composition contenant du vWF (facteur von Willebrand) hémostatique actif et procédé pour sa préparation
CN101163506B (zh) 2004-12-27 2012-09-26 巴克斯特国际公司 聚合物-von Willebrand因子偶联物
AU2007245190B2 (en) 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
AU2014202595A1 (en) * 2007-12-28 2014-06-05 Baxalta GmbH Recombinant VWF Formulations
SG187410A1 (en) * 2007-12-28 2013-02-28 Baxter Int Recombinant vwf formulations
MX2011001624A (es) * 2008-08-21 2011-03-28 Octapharma Ag Factor viii y ix humano producido en forma recombinante.
EP2349314B1 (fr) * 2008-10-21 2013-02-27 Baxter International Inc. Formulations de vwf recombinant lyophilisé
AU2010279463A1 (en) * 2009-08-04 2012-03-01 Baxter Healthcare S.A. Transgenic mouse knockout for FVIII and VWF - model of hemophilia A
JP2015515482A (ja) 2012-04-24 2015-05-28 ノヴォ ノルディスク アー／エス 血友病の治療に適する化合物
EP4424366A3 (fr) 2017-07-07 2024-12-04 Takeda Pharmaceutical Company Limited Traitement du saignement gastro-intestinal chez des patients atteints d'une maladie grave de von willebrand par administration de vwf recombiné
KR102788331B1 (ko) * 2017-07-07 2025-03-27 다케다 야쿠힌 고교 가부시키가이샤 재조합 vwf의 투여에 의해 대기 수술을 받은 중증 폰 빌레브란트 병을 가지고 있는 환자의 치료
EA202192140A1 (ru) 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386068A (en) * 1980-02-26 1983-05-31 Cutter Laboratories, Inc. Antihemophilic factor concentrate and method for preparation
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
NL8500961A (nl) * 1985-04-01 1986-11-03 Stichting Vrienden Van De Stic Cdna-codering voor de humane von willebrand-factor, plasmiden met een dergelijke cdna-codering respektievelijk fragmenten ervan, alsmede micro-organismen, welke dergelijke plasmiden bevatten.
US5043429B1 (en) * 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
FR2665449B1 (fr) * 1990-08-02 1995-04-14 Aquitaine Developp Transf Sang Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant.
DK0431129T3 (da) * 1989-06-15 1996-06-17 Rorer Int Overseas Fremgangsmåder til inaktivering af virus i viruskontaminerede farmaceutiske præparater
NL9000917A (nl) * 1989-10-25 1991-05-16 Holland Biotechnology Farmaceutisch preparaat met endoproteolytische activiteit; werkwijze voor endoproteolytische processing van (precursor) eiwitten en voor de (micro) biologische bereiding van eiwitten.
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
DE4434538C2 (de) * 1993-10-06 2000-08-10 Immuno Ag Verfahren zur Virusinaktivierung in Gegenwart eines Polyethers und eines chaotropen Agens
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor

Also Published As

Publication number Publication date
JPH09221432A (ja) 1997-08-26
EP0774261A3 (fr) 1998-06-03
EP0774261A2 (fr) 1997-05-21
NO964758D0 (no) 1996-11-08
CA2189947C (fr) 2009-06-02
CA2189947A1 (fr) 1997-05-11
US6005077A (en) 1999-12-21

Similar Documents

Publication Publication Date Title
CA2201714C (fr) Procede pour l'extraction du facteur willebrand a haute purete
NO964758L (no) Anvendelse av von Willebrand-faktor og farmasöytiske preparater
US6924151B2 (en) Stable factor VIII/vWF-complex
CA2202875C (fr) Procede de purification du facteur viii
DK162233B (da) Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
JP4335978B2 (ja) ｖＷＦプロペプチドを含む医薬調製物
US5484890A (en) Antihemophilic factor stabilization
JP4250769B2 (ja) 高度に精製されたｖＷＦまたは因子ＶＩＩＩ／ｖＷＦ複合体を得る方法
JP4741178B2 (ja) Ｖｉｉｉ因子：ｃ含有フォンビルブラント因子の濃縮物およびそれに関連する方法
Matsuda et al. Fibrinogen Kawaguchi: an abnormal fibrinogen characterized by defective release of fibrinopeptide A
AU1252700A (en) Pharmaceutical preparation containing a receptor-antagonist for treating blood-clotting disorders
Bolhuis et al. Molecular weight of human plasma factor VIII
Harris et al. Differentiation of antihemophilic factor (AHF) and von Willebrand factor (vWF) by their interaction with urea and selected amino acids